Dynamics of tumor‐specific cfDNA in response to therapy in multiple myeloma patients

OBJECTIVES: Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used for this purpose; however, this approach is site‐limited. Liquid biopsy represents a minimal...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur J Haematol
Hlavní autoři: Vrabel, David, Sedlarikova, Lenka, Besse, Lenka, Rihova, Lucie, Bezdekova, Renata, Almasi, Martina, Kubaczkova, Veronika, Brožová, Lucie, Jarkovsky, Jiri, Plonkova, Hana, Jelinek, Tomas, Sandecka, Viera, Stork, Martin, Pour, Ludek, Sevcikova, Sabina, Hajek, Roman
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7065130/
https://ncbi.nlm.nih.gov/pubmed/31763708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13358
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky